Clinical Trial Update: Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA) [Phase 1, Phase 2]

View source ↗

Summary

An update on a Phase 1/Phase 2, personalized antisense oligonucleotide trial for a single participant with MAPK8IP3-related neurodevelopmental disorder with or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurodevelopmental Disorder with or Without Variable Brain Abnormalities

Drugs mentioned

• Personalized antisense oligonucleotide targeting MAPK8IP3 (antisense oligonucleotide)

Snippet

Sponsor: n-Lorem Foundation | Conditions: Neurodevelopmental Disorder With or Without Variable Brain Abnormalities | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING